Omeprazole Gastro-resistant Capsules

Xuất bản: UTC +7

Cập nhật lần cuối: UTC +7

DOWNLOAD FILE PDF:VIEWDOWNLOAD
Omeprazole Gastro-resistant Capsules

If you find any inaccurate information, please let us know by providing your feedback here

Gastro-resistant Omeprazole Capsules

Action and use

Proton pump inhibitor; treatment of peptic ulcer disease.

DEFINITION

Omeprazole Gastro-resistant Capsules contain Omeprazole. They are covered with a gastro-resistant coating or prepared from granules or particles covered with a gastro-resistant coating.

The capsules comply with the requirements stated under Capsules and with the following requirements.

Content of omeprazole, C17H19N3O3S

95.0 to 105.0% of the stated amount.

IDENTIFICATION

In the Assay, record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 210 to 400 nm.

The UV spectrum of the principal peak in the chromatogram obtained with solution (1) is concordant with that of the peak in the chromatogram obtained with solution (2); the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).

TESTS

Dissolution

Comply with the dissolution test for tablets and capsules, Appendix XII B1.

Solution A: 11 volumes of 0.25M trisodium orthophosphate, 22 volumes of 0.5M disodium hydrogen orthophosphate and 67 volumes of water. Adjust to pH 11.0 with orthophosphoric acid or 10M sodium hydroxide.

Solution B: 0.1 volumes of 10M sodium hydroxide and 10 volumes of 0.05M phosphate buffer solution pH 4.5.

Solution C: 5.2 volumes of 1M anhydrous sodium dihydrogen orthophosphate and 63.2 volumes of 0.5M anhydrous disodium hydrogen orthophosphate and dilute to 1000 volumes with water. Adjust to pH 7.6 with orthophosphoric acid or 10M sodium hydroxide.

First stage (pH 4.5)

TEST CONDITIONS

(a) Use Apparatus 2, rotating the paddle at 100 revolutions per minute.

(b) Use 700 mL of 0.05M phosphate buffer solution pH 4.5, at a temperature of 37°, as the medium.

PROCEDURE

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) After 60 minutes withdraw 5 mL of the medium and filter (a 0.45-μm nylon filter is suitable). Dilute 1 volume of the filtrate to 5 volumes with solution A to produce a solution concentration expected to be similar to that of solution (2) and retain the samples for analysis. Proceed immediately to the final stage.

(2) 0.0002% w/v of omeprazole BPCRS in a mixture of 1 volume of solution A and 9 volumes of water.

CHROMATOGRAPHIC CONDITIONS

(a) Use a stainless steel column (15 cm × 2 mm) packed with octadecylsilyl silica gel for chromatography (5 μm) (Nucleosil C18 is suitable). Use a suitable guard column.

(b) Use isocratic elution and the mobile phase described below.

(c) Use a flow rate of 0.25 mL per minute.

(d) Use a column temperature of 30°.

(e) Use a detection wavelength of 302 nm.

(f) Inject 10 μL of each solution.

MOBILE PHASE

25 volumes of solution C, 35 volumes of water and 40 volumes of acetonitrile, adjusted to pH 7.6 with orthophosphoric acid or 10M sodium hydroxide.

When the chromatograms are recorded under the prescribed conditions, the retention time of omeprazole is about 4 minutes.

SYSTEM SUITABILITY

The symmetry factor of the peak due to omeprazole is not more than 2.0.

DETERMINATION OF CONTENT

Calculate the total content of C17H19N3O3S in the medium using the declared content of C17H19N3O3S in omeprazole BPCRS.

LIMITS

The amount of omeprazole released is not more than 10% of the stated amount.

Final stage (pH 6.8)

TEST CONDITIONS

(a) Use Apparatus 2, rotating the paddle at 100 revolutions per minute.

(b) Within 1 minute of withdrawing the medium at completion of the first stage, add 200 mL of solution B, at a temperature of 37°, to the vessel.

PROCEDURE

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) After 45 minutes withdraw a sample of the medium and filter (a 0.45-μm nylon filter is suitable). To a volume of the filtrate expected to contain the equivalent of 0.05 mg of omeprazole, add 1 volume of 0.25M sodium hydroxide and dilute to 25 volumes with solution A.

(2) 0.001% w/v of omeprazole BPCRS in a mixture of 1 volume of solution A and 9 volumes of water.

CHROMATOGRAPHIC CONDITIONS

The chromatographic conditions described under the first stage may be used.

SYSTEM SUITABILITY

The symmetry factor of the peak due to omeprazole is not more than 2.0.

DETERMINATION OF CONTENT

Calculate the total content of C17H19N3O3S, in the medium using the declared content of C17H19N3O3S in omeprazole BPCRS.

LIMITS

The amount of omeprazole released is not less than 75% (Q) of the stated amount.

Carry out the method for liquid chromatography, Appendix III D, using the following solutions in the mobile phase. The solutions should be prepared immediately before use.

(1) Disperse a quantity of finely powdered capsule contents containing the equivalent of 24 mg of Omeprazole in 150 mL of mobile phase, mix with the aid of ultrasound for 30 minutes, dilute with sufficient mobile phase to produce 200 mL, mix and filter.

(2) Dilute 1 volume of solution (1) to 20 volumes. Dilute 1 volume of this solution to 10 volumes.

(3) 0.01% w/v each of omeprazole BPCRS and omeprazole impurity D EPCRS.

(4) Dilute 1 volume of solution (2) to 5 volumes.

CHROMATOGRAPHIC CONDITIONS

(a) Use a stainless steel column (12.5 cm × 4.6 mm) packed with octylsilyl silica gel for chromatography (5 μm) (Nucleosil RP8 is suitable).

(b) Use isocratic elution and the mobile phase described below.

(c) Use a flow rate of 1 mL per minute.

(d) Use an ambient column temperature.

(e) Use a detection wavelength of 280 nm.

(f) Inject 40 μL of each solution.

(g) Allow the chromatography to proceed for 5 times the retention time of the peak due to omeprazole.

MOBILE PHASE

27 volumes of acetonitrile and 73 volumes of a 0.14% w/v solution of disodium hydrogen orthophosphate previously adjusted to pH 7.6 with orthophosphoric acid.

When the chromatograms are recorded under the prescribed conditions the relative retentions with respect to omeprazole (retention time about 9 minutes) are: impurity D, about 0.8; impurity C, about 3.4.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity D and omeprazole is at least 3.0.

LIMITS

In the chromatogram obtained with solution (1):

the area of any peak due to impurity D is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);

the area of any other secondary peak is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%)

the sum of the areas of any secondary peaks is not greater than four times the area of the principal peak in the chromatogram obtained with solution (2) (2.0%).

Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.1%).

ASSAY

Weigh the contents of 20 capsules. Mix and powder if necessary. Carry out the method for liquid chromatography,

Appendix III D, using the following solutions in the mobile phase.

(1) Shake a quantity of the mixed capsule contents containing the equivalent of 24 mg of Omeprazole in 150 mL of mobile phase, mix with the aid of ultrasound for 30 minutes, dilute with sufficient mobile phase to produce 200 mL, mix and filter. Dilute 1 volume to 10 volumes.

(2) 0.0012% w/v of omeprazole BPCRS.

(3) 0.01% w/v each of omeprazole BPCRS and omeprazole impurity D EPCRS.

CHROMATOGRAPHIC CONDITIONS

The chromatographic conditions described under Related substances may be used but with a detection wavelength of 305 nm.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity D and omeprazole is at least 3.0.

DETERMINATION OF CONTENT

Calculate the content of C17H19N3O3S in the capsules using the declared content of C17H19N3O3S in omeprazole BPCRS.

IMPURITIES

The impurities limited by this monograph include those listed under Omeprazole.

Leave a Reply

Your email address will not be published. Required fields are marked *